Wayne Hummer Investments L.L.C. trimmed its holdings in Amgen, Inc. (NASDAQ:AMGN) by 20.3% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 2,307 shares of the medical research company’s stock after selling 589 shares during the period. Wayne Hummer Investments L.L.C.’s holdings in Amgen were worth $430,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. Financial Advisory Service Inc. increased its stake in shares of Amgen by 0.3% during the second quarter. Financial Advisory Service Inc. now owns 1,974 shares of the medical research company’s stock worth $340,000 after acquiring an additional 5 shares during the period. Jackson Grant Investment Advisers Inc. increased its stake in shares of Amgen by 0.8% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after acquiring an additional 5 shares during the period. Capital Advisors Ltd. LLC increased its stake in shares of Amgen by 0.6% during the second quarter. Capital Advisors Ltd. LLC now owns 1,103 shares of the medical research company’s stock worth $190,000 after acquiring an additional 7 shares during the period. Ballentine Partners LLC grew its position in Amgen by 0.3% during the second quarter. Ballentine Partners LLC now owns 3,441 shares of the medical research company’s stock worth $620,000 after buying an additional 9 shares during the period. Finally, Hudock Capital Group LLC grew its position in Amgen by 0.5% during the second quarter. Hudock Capital Group LLC now owns 1,921 shares of the medical research company’s stock worth $330,000 after buying an additional 10 shares during the period. 78.48% of the stock is owned by institutional investors and hedge funds.
Shares of Amgen, Inc. (AMGN) opened at $189.28 on Friday. The company has a market cap of $137,400.44, a P/E ratio of 15.05, a PEG ratio of 2.77 and a beta of 1.36. Amgen, Inc. has a 1 year low of $150.38 and a 1 year high of $191.10. The company has a debt-to-equity ratio of 1.05, a current ratio of 6.07 and a quick ratio of 5.72.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, beating the consensus estimate of $3.11 by $0.16. The business had revenue of $5.77 billion for the quarter, compared to analyst estimates of $5.75 billion. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The company’s quarterly revenue was down .7% on a year-over-year basis. During the same period in the prior year, the business earned $3.02 earnings per share. sell-side analysts predict that Amgen, Inc. will post 12.69 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be given a $1.32 dividend. The ex-dividend date is Wednesday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 annualized dividend and a dividend yield of 2.79%. Amgen’s dividend payout ratio is currently 41.63%.
Amgen declared that its Board of Directors has initiated a stock repurchase plan on Wednesday, October 25th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.
Several brokerages have weighed in on AMGN. Credit Suisse Group restated a “neutral” rating and set a $186.00 target price (up from $177.00) on shares of Amgen in a research report on Friday, September 29th. BidaskClub upgraded shares of Amgen from a “sell” rating to a “hold” rating in a research report on Thursday. Royal Bank of Canada lowered their target price on shares of Amgen from $192.00 to $188.00 and set a “sector perform” rating on the stock in a research report on Thursday, October 26th. Oppenheimer set a $205.00 target price on shares of Amgen and gave the stock a “buy” rating in a research report on Friday, January 5th. Finally, Morgan Stanley lowered their target price on shares of Amgen from $196.00 to $193.00 and set an “overweight” rating on the stock in a research report on Thursday, October 26th. Fifteen equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $190.15.
In related news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $185.62, for a total transaction of $283,070.50. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Carbonnel Francois De sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total transaction of $694,440.00. The disclosure for this sale can be found here. Insiders sold 8,575 shares of company stock worth $1,508,836 over the last quarter. Company insiders own 0.19% of the company’s stock.
WARNING: “Wayne Hummer Investments L.L.C. Trims Stake in Amgen, Inc. (AMGN)” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/21/wayne-hummer-investments-l-l-c-trims-stake-in-amgen-inc-amgn.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.